PATENT CLAIM ANALYSIS

Application Number: 16068629
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.

Claim (Index 22):
The method of  claim 20  further comprising comparing the amount of the one or more Protocadherin FAT1 peptide fragments in the biological sample to the amount of one or more Protocadherin FAT1 peptide fragments in a biological sample from a cancer-free subject, wherein a higher amount of one or more Protocadherin FAT1 peptide fragments in the biological sample compared to the amount of one or more Protocadherin FAT1 peptide fragments in the biological sample from the cancer-free subject indicates that cancer is present in the subject or that the subject is predisposed to cancer.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.60976
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14800162', '13384014', '13464174', '14671062', '13813680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7382001248900953
- 35 USC 102 Novelty (BERT): 0.5382922813821048
- Combined Prediction Score: 0.7182093405392963
- Mean Citation Score: 313.977452
- Max Citation Score: 393.46048
- Similarity Product: 253.208270602417

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test